Intravenous fluid mismanagement: time for national stewardship and quality improvement Authors: Andrew Breen, Ashley Miller, Alan Timmins, Greg Barton, Justin Kirk-Bayley, Marcus John Edwards Peck, Huw John Davis, Jonathan Wilkinson Published: 2025 Introduction In 2013, National Institute for Health and Care Excellence (NICE) published Clinical Guideline 174 (CG174),1 guiding healthcare providers in UK hospitals on the safe administration of intravenous fluid therapy. This guidance was subsequently updated in 2017 and reviewed in 2021 without being substantially altered. The guidance provides educational insights into patients’ physiological requirements for water and electrolytes before categorising the indications for intravenous fluid prescription as routine maintenance, resuscitation, replacement and redistribution requirements. The guidance is supplemented by numerous posters, graphics and other aide-memoires to facilitate and promote good practice. Widespread implementation of this guidance will individualise and rationalise intravenous fluid prescribing practice and minimise the potential harms associated with incorrect or injudicious use of intravenous fluids. Given recent global shortages in access to intravenous fluids, adoption of best-practice, as well as new initiatives such as ‘Sip til Send’,2 ensures optimal and sustainable use of intravenous fluids across healthcare. Intravenous fluid mismanagement causes patient harm and increases costs The potential harms associated with intravenous fluid mismanagement arise from the effects of fluid overload, dehydration and electrolyte abnormalities. There are also harms associated with inappropriate prescription of colloid preparations. Intravenous fluids also need to be considered in the wider context of other routes of fluid and electrolyte administration, for example, enteral/parenteral nutrition, intravenous and effervescent medications. Some commonly occurring harms are listed in table 1. Table 1Commonly occurring harms associated with intravenous fluid prescriptionClinical risk categories Fluid overload Dehydration Electrolyte abnormalities Other outcomes Pulmonary and peripheral oedemaAcute kidney injuryHypernatraemia and hyponatraemiaGelatins and starches associated with acute kidney injuryDelayed recovery after surgery (wound healing, chest infections, mobility)Hypotension and shockHyperkalaemia and hypokalaemiaAlbumin associated with poorer outcomes from traumatic brain injuryChest infectionsArrhythmiasHyperchloraemic acidosis Commonly occurring harms associated with intravenous fluid prescription Fluid overload, dehydration and electrolyte imbalance each can lead to increased duration of hospital stay, incurring additional costs and reduced bed availability. Each of these can arise through the prescription of the incorrect fluid formulation or the incorrect volume of fluid. When associated with intravenous fluid prescribing errors, the consequent harms and additional costs are avoidable and unnecessary. Understanding the scale of intravenous fluid exposure and patient harm Intravenous fluid prescription is extremely commonplace across all inpatient medical specialties. It is a necessary component of the treatment of all patients with suspected sepsis, those undergoing major surgery and any patient unable to meet their daily requirements of fluid and electrolytes. Analysis of global intravenous fluid production and intravenous fluid sales reveals that billions of litres are produced each year. Further, data suggest that, across the UK, Australia and the USA alone, millions of exposures in millions of patients occur each year.3 These figures indicate that the overall prevalence of intravenous fluid use must be high, and the scale of intravenous fluid use suggests that improvements to prescribing practice have the potential to reduce harm across the entire inpatient population. Quality measurement and management in intravenous fluid prescription When CG174 was introduced, the authors suggested that one in five patients receiving intravenous fluids suffered harm.4 While such a figure is eye-catching, there is little data to describe the true extent of the harm associated with intravenous fluid prescription. This is unsurprising, given the difficulty of attributing harm to intravenous fluids in complex, heterogeneous patient populations. Outcome measures describing complications from intravenous fluid prescription are challenging to isolate: such complications are non-specific and occur in many disease processes, so establishing a cause and effect for intravenous fluid-related harm is difficult. For example, while adverse consequences of fluid overload include pulmonary oedema, delayed mobilisation after surgery or chest infection, it is complex to attribute episodes of any of these directly to the intravenous fluid management of a patient. Viewed from the opposite perspective, for a patient who develops a hospital-acquired pneumonia as a consequence of iatrogenic fluid overload, it is unlikely that the link between the two will be established and recorded. In the absence of reliable outcome measures, we must look towards structure and process measures to ensure that the correct actions are taken to minimise the potential harm of intravenous fluids. NICE Quality Standard 66 (QS66)5 presents four quality statements as follows: Hospitals must have an intravenous fluids lead who has overall responsibility for training, clinical governance, audit and review of intravenous fluid prescribing and patient outcomes. Hospitals must have an intravenous fluids lead who has overall responsibility for training, clinical governance, audit and review of intravenous fluid prescribing and patient outcomes. Adults receiving intravenous fluid therapy in hospital are cared for by healthcare professionals competent in assessing patients’ fluid and electrolyte needs, prescribing and administering intravenous fluids and monitoring patient response. Adults receiving intravenous fluid therapy in hospital are cared for by healthcare professionals competent in assessing patients’ fluid and electrolyte needs, prescribing and administering intravenous fluids and monitoring patient response. Adults receiving intravenous fluid therapy in hospital have an intravenous fluid management plan, determined by and reviewed by an expert, which includes the fluid and electrolyte prescription over the next 24 hours and arrangements for assessing patients and monitoring their plan. Adults receiving intravenous fluid therapy in hospital have an intravenous fluid management plan, determined by and reviewed by an expert, which includes the fluid and electrolyte prescription over the next 24 hours and arrangements for assessing patients and monitoring their plan. For adults who receive intravenous fluid therapy in hospital, clear incidents of fluid mismanagement are reported as critical incidents. For adults who receive intravenous fluid therapy in hospital, clear incidents of fluid mismanagement are reported as critical incidents. The requirement to ensure adequate training and to produce 24-hour management plans has been achieved on small-scale improvement projects6 and represents realistic standards. Regarding incident reporting, NICE suggested a number of surrogate outcomes that can be used when assessing the quality of intravenous fluid prescription. The occurrence of hyponatraemia and hypernatraemia during intravenous fluid infusion, as well as the occurrence of pulmonary oedema and peripheral oedema during intravenous fluid infusion, is proposed as reportable outcome measures to be investigated by an embedded governance process.5 The quality standards therefore highlight the need for leadership, education, patient management plans and incident reporting. A survey: current levels of engagement with NICE CG 174 in England We report the results of a survey of National Health Service (NHS) trusts in England investigating compliance with the recommendations in CG174 and QS66. In October 2022, we surveyed 141 NHS acute trusts in England using a request under the Freedom of Information Act. To gain a clearer understanding of the extent to which acute hospitals prioritise implementation and adherence to CG174 and QS66, we asked the following closed questions: Does your trust have a consultant lead for intravenous fluid therapy? If so, how many programmed activities of consultant time are allocated? Does your trust have a consultant lead for intravenous fluid therapy? If so, how many programmed activities of consultant time are allocated? Does your trust have a nursing lead for intravenous fluid therapy? If so, how many whole-time equivalents deliver this role? Does your trust have a nursing lead for intravenous fluid therapy? If so, how many whole-time equivalents deliver this role? Does your trust have an intravenous fluid therapy policy based on NICE (CG174 intravenous fluid therapy in adults in hospital)? Does your trust have an intravenous fluid therapy policy based on NICE (CG174 intravenous fluid therapy in adults in hospital)? Does your trust audit compliance with this intravenous fluid management policy? Does your trust audit compliance with this intravenous fluid management policy? Does your trust audit compliance with NICE QS66 (intravenous fluid therapy in adults in hospital)? Does your trust audit compliance with NICE QS66 (intravenous fluid therapy in adults in hospital)? Eighty-two responses were received from the 141 requests, a response rate of 59%. Table 2 contains a summary of the responses. Table 2Survey resultsQuestionPositive responses (%)Does your trust have a consultant lead for intravenous fluid therapy?16 (20%)Does your trust have a nursing lead for intravenous fluid therapy?12 (15%)Does your trust have an intravenous fluid therapy policy based on NICE Clinical Guideline 174?39 (48%)Does your trust audit compliance with this intravenous fluid management policy?27 (33%)Does your trust audit compliance with NICE Quality Standard 66?23 (28%)NICE, National Institute for Health and Care Excellence. Survey results NICE, National Institute for Health and Care Excellence. Less than half of acute NHS trusts in England who responded have produced an intravenous fluid therapy policy that is aligned to CG174, and only 33% audited compliance against this policy. Organisational leadership of intravenous fluid therapy, either from a lead consultant (20% of respondents) or lead nurse (15% of respondents), is lacking. This indicates that intravenous fluid therapy is not seen as a priority for quality improvement within the NHS in England and highlights the need for a nationwide improvement project to raise the standards of intravenous fluid prescription. Why is there poor engagement with an established NICE Guideline? Some possible explanations for poor engagement with NICE recommendations are as follows. Since the introduction of CG174, there has been very little national emphasis on compliance or quality improvement regarding the published guidance. In contrast to other national initiatives (such as venous thromboembolism prophylaxis or prevention of bloodstream infections), providers are not held to account by NHS England regarding intravenous fluid prescription. Since the introduction of CG174, there has been very little national emphasis on compliance or quality improvement regarding the published guidance. In contrast to other national initiatives (such as venous thromboembolism prophylaxis or prevention of bloodstream infections), providers are not held to account by NHS England regarding intravenous fluid prescription. System-wide quality improvement projects require significant resource and must be able to yield measurable patient benefit to justify resource allocation.7 8 The absence of outcome measures specific to intravenous fluid management makes it challenging to link improvement activity to patient outcomes. It is possible that the absence of suitable accountability measures has been a deterrent to the implementation of a national programme to improve compliance with CG174. System-wide quality improvement projects require significant resource and must be able to yield measurable patient benefit to justify resource allocation.7 8 The absence of outcome measures specific to intravenous fluid management makes it challenging to link improvement activity to patient outcomes. It is possible that the absence of suitable accountability measures has been a deterrent to the implementation of a national programme to improve compliance with CG174. While a majority of clinicians will agree that intravenous fluids can cause harm when prescribed incorrectly, evidence describing the extent of such harm at a system-wide level is scarce. Consequently, it may be difficult to generate a sense of urgency to implement change. While a majority of clinicians will agree that intravenous fluids can cause harm when prescribed incorrectly, evidence describing the extent of such harm at a system-wide level is scarce. Consequently, it may be difficult to generate a sense of urgency to implement change. A key component of safe intravenous fluid prescription is the accurate measurement of fluid balance and patient weight. The widespread implementation of detailed fluid balance and weight recording for all patients receiving intravenous fluids is challenging when resources are constrained. Nonetheless, the benefits of both of these extend beyond safe fluid prescription, enhancing nutrition management and accurate drug dosing. A key component of safe intravenous fluid prescription is the accurate measurement of fluid balance and patient weight. The widespread implementation of detailed fluid balance and weight recording for all patients receiving intravenous fluids is challenging when resources are constrained. Nonetheless, the benefits of both of these extend beyond safe fluid prescription, enhancing nutrition management and accurate drug dosing. Given that, under the Freedom of Information Act, responses are required by law and should be received within 20 working days of receipt of the request, a response rate of 59% is lower than expected and may indicate bias towards Trusts already engaged in quality improvement efforts. It is possible that engagement among Trusts is poorer than the survey revealed. Education in good prescribing practices All acute clinicians have a role in intravenous fluid prescription, and it is considered core knowledge for prescribers. Despite this, education regarding intravenous fluid prescription is not consistently delivered to prescribers. Although a number of resources exist to guide the education of prescribers, there is currently no national education programme aligned to NICE CG174 for either students or professionals. Medical graduates are expected to be able to prescribe medicines safely as soon as they commence employment,9 but consistently report feeling unprepared to prescribe intravenous fluids.10 Education resources targeting intravenous fluid prescribers improve understanding of the principles of intravenous fluid requirements and clinical application, as well as confidence of prescribers.11 Among specialists in intensive care medicine and anaesthesia, understanding of intravenous fluid prescription requirements is lacking. A survey of 1045 healthcare professionals working predominantly in these specialties across 95 countries demonstrated poor knowledge of intravenous fluid physiology and wide variation in prescribing patterns.12 Brief education interventions have been shown to be effective at aligning intravenous fluid prescribing with current guidelines13 14 and could be employed at a national level to improve practice and minimise harm. Clinical decision support tools Clinical decision support (CDS) tools, especially those integrated with prescribing systems, aim to improve outcomes by promoting adherence to guidelines, using patient-specific information to individualise prescriptions (eg, patient weight, electrolyte measurements) and minimising avoidable harm through prescribing errors.1517 CDS tools are therefore well-suited to optimising intravenous fluid prescribing, ensuring adherence to clinical guidelines based on current evidence. The implementation of CDS-based initiatives has been shown to enhance prescribing safety, minimising risks associated with fluid overload, electrolyte imbalances and inappropriate fluid selection.18 Overall, the integration of CDS tools into intravenous fluid prescribing workflows represents a significant opportunity to promote patient safety and clinical efficiency. By leveraging evidence-based decision support, healthcare providers can improve the precision of intravenous fluid prescription, enhance adherence to guidelines and reduce the harms associated with intravenous fluid mismanagement. Experience of a national intravenous fluid improvement initiative The potential for harm reduction through a large-scale intervention across entire acute hospital system has been recognised previously. The National IV Fluid Improvement Programme in Scotland19 was launched in February 2018. It was a Scottish Government initiative, run through the Modernising Patient Pathways Programme, aiming to support implementation of standard guidance on fluid therapy and support this via education, training and data collection to reduce variation.20 The programme provided support and resources for Boards to change practice to reflect NICE CG174. By the end of 2019, informal data collection indicated an improvement in following recommendations, but before formal evaluation could start in 2020, the pandemic started. Subsequently many of the staff involved were redeployed and priorities changed. After the pandemic, NHS recovery planning resulted in changed priorities; intravenous fluids were no longer seen as a priority and funding was not renewed. Still, the Scottish programme met with considerable success in improving practice across a large geographical area and population. In the absence of an official account regarding why the programme was deprioritised, it is not which clear barriers and enablers which could be applied to a larger UK project. Nonetheless, the experience gained in Scotland could provide valuable lessons for a larger project to be attempted across the UK. Intravenous fluid stewardship Intravenous fluid stewardship refers to the systematic approach to optimising the administration of intravenous fluids to ensure effective, safe and patient-specific care while minimising potential harms. This concept focuses on individualised prescribing that aligns with the physiological needs of patients and the specific clinical context, avoiding common harms such as fluid overload or electrolyte disturbances. Stewardship programmes emphasise adherence to evidence-based guidelines, weight-based prescriptions and precise fluid balance monitoring, using multidisciplinary collaboration to improve clinical outcomes. Fluid balance monitoring and associated improvement interventions, in particular, present challenges. Nonetheless, improvements are achievable and can make an important difference to the quality of fluid management.21 Doctors, pharmacists and nurses all have key roles in any fluid stewardship programme. Fluid stewardship frameworks can mitigate risks of over-resuscitation in critical care settings with tailored intervention.22 Volume overload by maintenance intravenous fluid mismanagement is commonplace throughout acute care settings and can be minimised by a comprehensive fluid stewardship approach which takes account of all sources of fluid and electrolyte administration (eg, intravenous medications).23 To strengthen the conceptual basis of fluid stewardship, its structure can be aligned with the well-established framework used across healthcare quality improvement: structure, process and outcome. The structural elements encompass organisational policy, leadership, education resources and prescribing infrastructure aligned with NICE CG174 and QS66. Process elements include competency assessment, audit and bedside review of intravenous fluid prescriptions. Outcome measures relate to reductions in iatrogenic harm, such as fluid overload, electrolyte disturbance and avoidable acute kidney injury. A call to action for a national intravenous fluid stewardship programme NICE CG174 provides clear guidance on intravenous fluid prescribing. This guidance was produced, and is regularly reviewed, by an expert panel in accordance with NICE procedures. The authors of this article believe that CG174 contains no controversial or incorrect recommendations and that implementing this guidance in every hospital in the UK would reduce the patient harm caused by intravenous fluid mismanagement. The scale of patient exposure to intravenous fluids strongly suggests that the potential for harm reduction is very high. The following measures will promote widespread adoption of, and adherence to, CG174 recommendations: Consistent education on intravenous fluid prescribing practice across all medical, pharmacy and nursing undergraduate courses. Key principles must be emphasised across all prescribing groups, with CG174 recommendations at the centre of educational resources. Consistent education on intravenous fluid prescribing practice across all medical, pharmacy and nursing undergraduate courses. Key principles must be emphasised across all prescribing groups, with CG174 recommendations at the centre of educational resources. Re-education of doctors, pharmacists and nurses, again emphasising the key principles and recommendations contained in CG174. Re-education of doctors, pharmacists and nurses, again emphasising the key principles and recommendations contained in CG174. Mandatory introduction of prescribing support tools (for electronic and paper-based systems) to simplify accurate prescribing and encourage adherence to CG174 recommendations through the use of prescribing protocols. These could include prompts within paper prescription proformas, weight-based nomograms and recommendations on the choice of intravenous fluids. Online support tools, such as the one produced by Health Improvement Scotland,24 are already available for this purpose. Mandatory introduction of prescribing support tools (for electronic and paper-based systems) to simplify accurate prescribing and encourage adherence to CG174 recommendations through the use of prescribing protocols. These could include prompts within paper prescription proformas, weight-based nomograms and recommendations on the choice of intravenous fluids. Online support tools, such as the one produced by Health Improvement Scotland,24 are already available for this purpose. A national quality improvement programme, applicable to all healthcare settings in which intravenous fluids are prescribed, targeting improvement in the following structure and process measures:Introduction of local intravenous fluid prescribing policies that are aligned to the CG174 recommendations.Introduction of intravenous fluid leadership roles for all acute provider organisations to steer a wider intravenous fluid stewardship group with multispecialty and multiprofessional representation.Local delivery of educational material to all professionals involved in the prescription and administration of intravenous fluids.Incident reporting mechanisms following the recommendations included in QS66. A national quality improvement programme, applicable to all healthcare settings in which intravenous fluids are prescribed, targeting improvement in the following structure and process measures: Introduction of local intravenous fluid prescribing policies that are aligned to the CG174 recommendations. Introduction of local intravenous fluid prescribing policies that are aligned to the CG174 recommendations. Introduction of intravenous fluid leadership roles for all acute provider organisations to steer a wider intravenous fluid stewardship group with multispecialty and multiprofessional representation. Introduction of intravenous fluid leadership roles for all acute provider organisations to steer a wider intravenous fluid stewardship group with multispecialty and multiprofessional representation. Local delivery of educational material to all professionals involved in the prescription and administration of intravenous fluids. Local delivery of educational material to all professionals involved in the prescription and administration of intravenous fluids. Incident reporting mechanisms following the recommendations included in QS66. Incident reporting mechanisms following the recommendations included in QS66. Of the proposed measures, key foundational steps are the introduction of leadership at a local level and the widespread use of prescribing support tools aligned to NICE CG174. Conclusion The management of intravenous fluid therapy in hospitals is critical to ensuring patient safety and improving clinical outcomes. While NICE CG174 provides comprehensive recommendations for the safe and effective use of intravenous fluids, the limited engagement with these guidelines across NHS trusts, as shown by our survey, highlights a significant gap in practice. Addressing this gap requires a coordinated effort to prioritise intravenous fluid stewardship, underpinned by robust leadership, consistent education and system-wide quality improvement initiatives. A national framework for intravenous fluid management—incorporating mandatory compliance policies, enhanced training programmes and effective prescribing tools—can significantly reduce patient harm and healthcare costs. By fostering accountability and embedding these principles within clinical practice, the NHS can set a benchmark for excellence in intravenous fluid therapy. Implementing these changes is not just an opportunity for improvement but an imperative to safeguard hospitalised patients from avoidable harm.